1. Home
  2. CTO vs OMER Comparison

CTO vs OMER Comparison

Compare CTO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTO Realty Growth Inc.

CTO

CTO Realty Growth Inc.

HOLD

Current Price

$18.02

Market Cap

552.9M

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$15.79

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTO
OMER
Founded
1902
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.9M
628.9M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
CTO
OMER
Price
$18.02
$15.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$22.00
$27.50
AVG Volume (30 Days)
300.8K
3.0M
Earning Date
10-28-2025
11-13-2025
Dividend Yield
8.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$146,948,000.00
N/A
Revenue This Year
$20.87
N/A
Revenue Next Year
$4.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.84
N/A
52 Week Low
$15.07
$2.95
52 Week High
$20.88
$17.65

Technical Indicators

Market Signals
Indicator
CTO
OMER
Relative Strength Index (RSI) 54.72 76.40
Support Level $17.59 $8.60
Resistance Level $18.64 $17.65
Average True Range (ATR) 0.31 1.01
MACD -0.05 0.37
Stochastic Oscillator 39.34 80.43

Price Performance

Historical Comparison
CTO
OMER

About CTO CTO Realty Growth Inc.

CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: